NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 7 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Hikal Q2 FY27 Earnings Call: Revenue at ₹434 Cr, Net Loss at ₹6 Cr Amid Input Cost Pressure
Hikal released its Q2 & H1 FY27 earnings call transcript, reporting Q2 revenue of ₹434 crore with an EBITDA margin of 10.3% (₹45 crore) and a net loss of ₹6 crore. For H1 FY27, revenue reached ₹837 crore with EBITDA of ₹82 crore and a net loss of ₹14 crore, impacted by raw material price inflation exceeding 100% on key inputs. The company reaffirmed its full-year guidance targeting mid-teens revenue growth and margin recovery, supported by a newly signed multi-year European agrochemical CDMO contract. Quality remediation remains in focus, having received Swissmedic GMP compliance for Bengaluru while targeting a US FDA reinspection by the end of FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுHikal published the complete management transcript discussing its Q2/H1 FY27 operational performance, contract wins, and cost pressures.
ஏன் இது முக்கியம்Provides detailed operational insight into the duration of raw material cost headwinds, debt status (D/E at 0.52), and commercial ramp-ups across CDMO and Panoli facilities.
📅 குறுகிய காலம்Performance will remain subdued until raw material price increases (>100% on key inputs) can be fully passed on to CDMO clients in the next 1-2 quarters.
📈 நீண்ட காலம்Medium-to-long term turnaround relies on commercializing the multi-year European CDMO contract, scaling the Panoli facility, and successfully clearing the US FDA reinspection.
⚠ அபாய எச்சரிக்கைகள்
Continued Chinese price dumping in crop protection segment
Severe raw material cost inflation depressing operating margins
Pending US FDA clearance for the Bengaluru facility
👀 கவனிக்க வேண்டியவை
Track the timeline of the targeted US FDA reinspection at the Bengaluru facility by late FY27 and monitor margin recovery in H2 as input cost pass-throughs take effect.
Hikal Q2 FY27: Revenue Rises 36% YoY to ₹434 Cr, Net Loss Narrows to ₹6 Cr
Hikal Limited released its Q2 FY27 investor presentation, reporting a 36% YoY increase in consolidated revenue to ₹434 crore compared to ₹319 crore in Q2 FY26. Operating performance improved significantly as EBITDA surged 524% YoY to ₹45 crore (10.3% margin) from ₹8 crore (2.6% margin). Net loss narrowed to ₹6 crore from a loss of ₹35 crore in the corresponding prior-year quarter. Growth was driven by the Pharmaceuticals segment, which grew 47% YoY to ₹278 crore, while Crop Protection grew 21% YoY to ₹156 crore despite Chinese pricing pressures.
உச்சம் நம்பிக்கை
என்ன மாறியதுHikal presented its Q2 FY27 performance showing sequential and annual operational recovery, Swissmedic GMP approval for Bengaluru API site, and commercial launch at Panoli for personal care.
ஏன் இது முக்கியம்Demonstrates stabilization in operating margins back above 10% after FY26 losses, backed by an expanding CDMO pipeline and new commercial contracts.
📅 குறுகிய காலம்Earnings sentiment should improve as operational EBITDA rose to ₹45 crore and losses narrowed, though the company remains in net loss territory.
📈 நீண்ட காலம்Commercialization of personal care at Panoli and multi-year CDMO contracts in agrochemicals support management's guidance of mid-teens revenue growth and profit expansion.
⚠ அபாய எச்சரிக்கைகள்
Crop Protection margins pressured by elevated raw material costs and Chinese competition
Continued net losses at the consolidated bottom line
👀 கவனிக்க வேண்டியவை
Track the turnaround in net profitability in H2 FY27 and monitor margin recovery in the Crop Protection division amid ongoing Chinese competitive pressures.
Hikal Signs Multi-Year Global CDMO Contract with European Agrochemical Major
Hikal Limited has secured a multi-year global CDMO contract with a Europe-based agrochemical innovator to supply a specialised agrochemical product worldwide. The agreement comes after approximately three years of process development and scale-up by Hikal's Crop Protection division. Commercial launch is targeted for late FY 2026–27, with revenue ramp-up dependent on progressive regulatory approvals. While total contract value was not disclosed, this win could help turnaround performance following a loss-making TTM period (PAT of Rs -34 Cr on Rs 1,734 Cr revenue).
உச்சம் நம்பிக்கை
என்ன மாறியதுHikal transitioned a 3-year collaborative process development project into a binding multi-year commercial CDMO manufacturing contract.
ஏன் இது முக்கியம்Provides long-term revenue visibility for Hikal's Crop Protection unit, which has faced pricing pressure, helping utilize existing infrastructure across its 5 manufacturing sites.
Contract value: வெளியிடப்படவில்லைDevelopment duration: nearly 3 yearsCommercial launch target: end of FY 2026–27TTM Revenue base: Rs 1734 கோடி
📅 குறுகிய காலம்Positive sentiment driver for the stock given recent loss-making quarters, though immediate P&L impact will be minimal until commercial supplies commence.
📈 நீண்ட காலம்Strengthens Hikal's high-margin CDMO profile and helps de-risk its top-heavy crop protection product concentration over the next multi-year cycle.
⚠ அபாய எச்சரிக்கைகள்
Contract value and minimum volume commitments are not disclosed
Revenue ramp-up relies on obtaining global regulatory approvals
Execution timeline pushes commercial revenue to late FY 2026–27
👀 கவனிக்க வேண்டியவை
Track subsequent quarterly updates for disclosure on commercial supply timelines toward late FY 2026–27 and regulatory clearance progress in target export markets.
Hikal Bengaluru API Facility Secures Swissmedic GMP Certification
Hikal Limited announced that its active pharmaceutical ingredient (API) facility in Bengaluru has been granted a Certificate of GMP Compliance by Swissmedic, Switzerland's therapeutic products agency. The certification confirms adherence to Good Manufacturing Practice standards under the Mutual Recognition Agreement between Switzerland and the European Union. This regulatory milestone follows earlier successful inspections by Brazil's ANVISA and Japan's PMDA, enhancing market access for Hikal's pharmaceutical segment, which generated part of its ₹1,734 Cr TTM revenue.
உச்சம் நம்பிக்கை
என்ன மாறியதுHikal's Bengaluru API facility received official GMP compliance certification from Swissmedic, expanding its validated regulatory footprint.
ஏன் இது முக்கியம்Enables supply of APIs into Switzerland and EU markets under mutual recognition, supporting pharmaceutical export growth and client acquisitions in high-margin regulated regions.
Announcement date: அக்டோபர் 30, 2026Total manufacturing facilities: 5Company TTM revenue: ₹1734 கோடி
📅 குறுகிய காலம்Positive sentiment for the stock, though immediate revenue impact will depend on commercial contract execution and product filings.
📈 நீண்ட காலம்Strengthens global regulatory credentials alongside ANVISA and PMDA, facilitating European market access and supporting long-term CDMO client acquisition.
⚠ அபாய எச்சரிக்கைகள்
Client and product concentration in Gabapentin (35-40% of pharma revenue)
Commercialization timelines for new European supply contracts
👀 கவனிக்க வேண்டியவை
Track whether this certification aids contract inflows or CDMO order wins in Europe over coming quarters, and watch for margin recovery in upcoming quarterly earnings.
Hikal Board Reshuffle: Jai Hiremath Steps Down as Exec Chairman; Anish Swadi Appointed CEO-Animal Health
Hikal announced major board leadership changes effective October 01, 2026. Founder Mr. Jai Hiremath has completed his term as Executive Chairman and has been appointed Chairman Emeritus for a 5-year period without board or officer status. Concurrently, Mrs. Sugandha Hiremath resigned as Non-Executive Director effective September 30, 2026, citing personal commitments. Additionally, Mr. Anish Swadi was elevated to CEO - Animal Health and Specialty Ingredients, a key strategic growth vertical for the company.
உச்சம் நம்பிக்கை
என்ன மாறியதுExecutive Chairman Jai Hiremath stepped down to become Chairman Emeritus, Sugandha Hiremath exited the Board, and Anish Swadi took charge as CEO of Animal Health and Specialty Ingredients.
ஏன் இது முக்கியம்Represents a generational/governance transition at the promoter level while formalizing executive leadership over the high-growth Animal Health and CDMO portfolio.
Chairman Emeritus tenure: 5 yearsEffective date of changes: அக்டோபர் 01, 2026Mrs. Sugandha Hiremath board tenure: 1992 முதல்
📅 குறுகிய காலம்Governance changes are orderly; markets will watch for announcements regarding a new Board Chairperson or further executive realignments.
📈 நீண்ட காலம்The elevation of dedicated leadership for the Animal Health segment aligns with the company's stated mid-to-long term turnaround and margin expansion strategy.
⚠ அபாய எச்சரிக்கைகள்
Loss of long-standing Board leadership during a period of turnaround (TTM PAT at Rs -34 Cr)
Execution risk in scaling the Animal Health segment
👀 கவனிக்க வேண்டியவை
Track the succession at the Board's top executive level and monitor performance execution in the Animal Health vertical, which is a stated primary growth driver.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Hikal Shareholders Approve Sameer Hiremath as CMD for 5-Year Term; Reaffirms Panoli Expansion
Hikal Limited announced that shareholders approved the appointment of Mr. Sameer Hiremath as Chairman and Managing Director for a 5-year term from October 1, 2026, to September 30, 2031. Shareholders at the 38th AGM also approved the FY26 audited accounts and a final dividend of Rs 0.40 per share. Additionally, the company highlighted the commercial commencement of personal care manufacturing at its new Panoli, Gujarat cGMP facility, marking an entry into beauty and personal care. This leadership continuity comes amid challenging operational performance, with Hikal reporting a net loss of Rs 34 Cr over the TTM period.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders formally approved Sameer Hiremath as Chairman & MD for five years through September 2031 and approved a Rs 0.40/share final dividend.
ஏன் இது முக்கியம்Provides leadership stability and confirms commercialization of the Panoli facility, supporting strategic diversification into personal care and specialty chemicals to offset weak agrochem pricing.
CMD Tenure: 5 years (Oct 1, 2026 to Sep 30, 2031)Final Dividend per share: Rs 0.40TTM Net Loss: Rs -34 CrAnnual General Meeting: 38th AGM
📅 குறுகிய காலம்Neutral to mildly positive as leadership succession uncertainty is settled and AGM approvals (including dividend) are formalized.
📈 நீண்ட காலம்Execution at the Panoli facility will be critical to turn around profitability, given Hikal's FY26 net loss of Rs 49.3 Cr and low ROCE of 4.0%.
⚠ அபாய எச்சரிக்கைகள்
Ongoing operational drag reflected in TTM net losses of Rs 34 Cr
High product concentration in Gabapentin and top crop protection molecules
👀 கவனிக்க வேண்டியவை
Track capacity ramp-up and revenue contribution from the newly commissioned Panoli personal care facility in upcoming quarterly results, alongside profitability recovery following FY26 net losses.
Hikal Enters Personal Care: Starts Commercial Production at cGMP Panoli Facility
Hikal Limited has commenced commercial production for its new Personal Care business following the commissioning of a repurposed cGMP multipurpose facility at Panoli, Gujarat. The initial portfolio focuses on skin care and second-generation UV filters, with initial production batches manufactured and validated with customers. The company aims to build this into a high-value growth platform alongside its existing Pharma, Crop Protection, and Animal Health segments. This strategic entry comes as Hikal works to rebound from a challenging TTM net loss of Rs -34 crore on TTM revenue of Rs 1,734 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுHikal officially initiated commercial-scale production and completed initial batch validation for its new personal care vertical at the repurposed Panoli site.
ஏன் இது முக்கியம்Provides a new diversification avenue away from the margin-pressured crop protection and API businesses, potentially boosting profitability given the higher-margin profile of specialty personal care ingredients.
Announcement Date: செப்டம்பர் 22, 2026EcoVadis Score: 84/100EcoVadis Percentile Ranking: 97-வது பர்சன்டைல்Capex or Capacity Added: வெளியிடப்படவில்லை
📅 குறுகிய காலம்Positive sentiment driver as the company successfully achieves operational commissioning of a new business vertical.
📈 நீண்ட காலம்Could structurally improve product mix and margins over the coming years if customer audits convert into stable commercial off-take contracts.
⚠ அபாய எச்சரிக்கைகள்
Commercial uptake and scale-up timelines remain dependent on customer qualification approvals.
Financial investment amount and expected revenue contribution are not disclosed.
👀 கவனிக்க வேண்டியவை
Track the upcoming quarterly revenue disclosures to see how quickly personal care sales ramp up and whether capacity utilization figures or revenue targets for Panoli are provided.
Hikal Appoints Sameer Hiremath as Chairman & MD for a 5-Year Term From Oct 1, 2026
Hikal Limited's Board of Directors has approved the appointment of Mr. Sameer Hiremath as Chairman and Managing Director for a 5-year tenure effective October 1, 2026, to September 30, 2031, subject to shareholder approval. Mr. Hiremath currently serves as Vice Chairman and Managing Director and has been with the company for nearly three decades. The transition ensures executive continuity for the bulk drugs and CDMO company (market cap Rs 2,600 Cr), which is currently working through operational turnarounds following a TTM net loss of Rs 34 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுElevation of Vice Chairman & MD Sameer Hiremath to the consolidated role of Chairman and Managing Director starting October 1, 2026.
ஏன் இது முக்கியம்Ensures promoter-led leadership stability and strategic continuity across Hikal's manufacturing, CDMO pipeline, and business development initiatives.
Term length: 5 (Five) yearsTenure start date: அக்டோபர் 01, 2026Tenure end date: செப்டம்பர் 30, 2031
📅 குறுகிய காலம்Neutral reaction expected since Mr. Hiremath is already an established executive leader within the company.
📈 நீண்ட காலம்Provides governance and operational continuity as Hikal seeks margin recovery across its pharma and crop protection portfolios.
⚠ அபாய எச்சரிக்கைகள்
Subject to shareholder approval at the AGM
Promoter family succession
👀 கவனிக்க வேண்டியவை
Track shareholder voting on the appointment at the ensuing AGM and monitor operational execution in the CDMO and API business units amid ongoing turnaround efforts.
Hikal Targets US FDA Re-inspection by FY27-End; Rs 900 Cr Capex Invested Over 4 Years
Hikal reported Q1 FY27 revenue of ₹403 cr with an EBITDA margin of 9.2%, signaling a recovery from recent regulatory disruptions. The company is currently remediating a US FDA warning letter received in August 2025 and expects a re-inspection by the end of the current fiscal year. Management highlighted a total investment of ₹900 cr over the last four years, with ₹600 cr specifically for growth projects. The Animal Health segment is projected to reach ₹400 cr in revenue by FY30, while a new Personal Care line has recently commenced commercial production.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from regulatory-led disruption to execution-led growth, commissioning a new Personal Care manufacturing line and a pilot plant at Panoli.
ஏன் இது முக்கியம்Resolving the US FDA warning letter is essential for Hikal to normalize its pharma operations and accelerate its CDMO pipeline, which has been constrained by regulatory status.
Q1 FY27 Revenue: ₹403 கோடி4-Year Total Capex: ₹900 கோடிGrowth Capex vs Market Cap: ~22%EBITDA லாப வரம்பு: 9.2%Animal Health FY30 Target: ₹400 கோடி
📅 குறுகிய காலம்The stock may remain range-bound as the market waits for concrete progress on the US FDA re-inspection and stabilization of margins in the Crop Protection segment.
📈 நீண்ட காலம்Structural growth is tied to the scale-up of the Animal Health and Personal Care segments and the successful de-risking of manufacturing from Bangalore to Panoli.
⚠ அபாய எச்சரிக்கைகள்
US FDA Warning Letter remediation risk
Pricing pressure in Crop Protection due to Chinese overcapacity
High product concentration in Gabapentin (35-40% of pharma revenue)
👀 கவனிக்க வேண்டியவை
Investors should monitor the successful completion of US FDA remediation milestones and the specific timeline for the re-inspection of the Bangalore facility, which is critical for unlocking higher-margin pharma growth.
Q1 FY27 Results: Revenue at ₹403 Cr, EBITDA Margin Expands 260 bps to 9.2%
Hikal reported a 6.2% YoY revenue growth to ₹403 Cr for Q1 FY27, driven by a 15.2% recovery in the Pharmaceutical segment (₹233 Cr). While the company remains in a net loss position of ₹7 Cr, this is a significant improvement from the ₹22 Cr loss in Q1 FY26. EBITDA grew 47.4% YoY to ₹37 Cr, reflecting margin expansion despite higher input costs in the Crop Protection segment. The company is in the final stages of US FDA remediation and recently commercialized its Personal Care facility in July 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுHikal is transitioning from regulatory-led disruption toward growth, evidenced by narrowing losses and a recovery in the Pharma segment despite headwinds in Crop Protection.
ஏன் இது முக்கியம்The margin expansion and narrowing losses indicate operational stabilization after a difficult FY26 (TTM PAT of -₹49 Cr). The shift toward higher-value APIs and new segments like Personal Care are key to long-term profitability.
📅 குறுகிய காலம்The market may view the narrowing losses and margin expansion as a sign of a turnaround, though the continued net loss and Crop Protection weakness remain concerns.
📈 நீண்ட காலம்Structural recovery depends on successful US FDA clearance, scaling the Animal Health business, and the contribution of the new Personal Care segment to diversify revenue.
⚠ அபாய எச்சரிக்கைகள்
Continued net losses
US FDA regulatory uncertainty (reinspection pending)
High input costs impacting Crop Protection margins
High client concentration in Gabapentin (35-40% of pharma revenue)
👀 கவனிக்க வேண்டியவை
Monitor the timeline for the US FDA reinspection expected within FY27 and the revenue ramp-up from the newly commissioned Personal Care facility at Panoli.
Hikal Q1 FY27: Revenue up 6% YoY to ₹402.8 Cr; Net Loss narrows to ₹7.3 Cr
Hikal reported consolidated revenue of ₹402.8 Cr for Q1 FY27, a 5.9% increase compared to ₹380.4 Cr in Q1 FY26, though it declined 22.4% sequentially from Q4 FY26. The company posted a consolidated net loss of ₹7.3 Cr, an improvement from the ₹23.1 Cr loss in the same period last year. Performance was aided by an exceptional gain of ₹8.9 Cr from salary restructuring, while the Pharma segment (₹233.3 Cr revenue) remains impacted by a 2025 USFDA warning letter. The Crop Protection segment reported an EBIT loss of ₹6.0 Cr, reflecting continued margin pressure.
உச்சம் நம்பிக்கை
என்ன மாறியதுHikal has shown a year-on-year recovery in revenue and narrowing losses, though it remains in the red and saw a significant sequential drop in performance compared to Q4 FY26.
ஏன் இது முக்கியம்The company is navigating regulatory headwinds in its Pharma business and cyclical pressure in Crop Protection; the narrowing loss suggests cost-control measures are taking effect.
Consolidated Revenue (Q1 FY27): ₹402.8 கோடிConsolidated Net Loss (Q1 FY27): ₹7.3 கோடிPharma Segment Revenue: ₹233.3 கோடிCrop Protection EBIT: ₹-6.0 கோடிExceptional Gain: ₹8.9 கோடிRevenue vs TTM Revenue: ~23.5%
📅 குறுகிய காலம்The stock may see neutral to slightly cautious sentiment as the sequential decline in revenue and continued losses offset the year-on-year improvement.
📈 நீண்ட காலம்Structural recovery depends on clearing the USFDA warning letter and the successful scale-up of new molecules in the animal health and specialty chemicals segments.
⚠ அபாய எச்சரிக்கைகள்
Ongoing USFDA warning letter impact on Pharma sales
Loss-making Crop Protection segment
Pending environmental litigation in the Supreme Court with ₹17.45 Cr potential liability
👀 கவனிக்க வேண்டியவை
Monitor the resolution status of the USFDA warning letter for the Jigani facility and the recovery of profitability in the Crop Protection segment.
Hikal Q4 FY26 Revenue at ₹519 Cr; EBITDA Margin Recovers to 20.3% Amid Operational Turnaround
Hikal Limited reported a strong operational recovery in Q4 FY26 with revenue of ₹519 crores and EBITDA margins expanding to 20.3%. For the full year FY26, revenue stood at ₹1,713 crores, though the company reported a PBT loss of ₹79.3 crores primarily due to ₹85 crores in exceptional items related to labor codes and asset impairments. Both Pharma and Crop Protection segments showed significant sequential margin improvements in Q4, reaching 12% and 17.1% respectively. The company successfully reduced its debt-to-equity ratio to 0.56, signaling improved financial discipline.
முக்கிய அம்சங்கள்
Q4 FY26 EBITDA margin improved to 20.3% compared to the annual average of 12.9%.Pharma segment capacity utilization reached 80-85% with a target to increase DMF filings to 5-6 annually.Crop Protection EBIT margin surged to 17.1% in Q4, indicating a recovery from global inventory corrections.Exceptional items of ₹85 crores for the full year impacted the bottom line, including a ₹47 crore impairment in Q4.Debt-to-equity ratio improved from 0.59 to 0.56 as of March 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors should focus on the sharp sequential recovery in margins and management's guidance for a stronger FY27. The successful transition from remediation to growth, coupled with new R&D capabilities in HPAPI, makes Hikal a key watch for a cyclical turnaround.
Hikal Promoter B.N. Kalyani Declares Nil Encumbrance on 34.01% Stake for FY26
Promoter B.N. Kalyani has submitted an annual disclosure confirming that no shares held by the promoter group in Hikal Limited were pledged or encumbered during the financial year 2025-26. The declaration specifically covers 38,667,375 shares (31.36%) held by Kalyani Investment Company Limited and 3,273,375 shares (2.65%) held by BF Investment Limited. This filing is a mandatory annual requirement under Regulation 31(4) of SEBI (SAST) Regulations. It provides assurance to shareholders regarding the financial stability of the promoters and the lack of debt-related risks against their equity.
முக்கிய அம்சங்கள்
Promoter B.N. Kalyani confirms zero encumbrance on shares held by KICL and BFIL for FY 2025-26.Kalyani Investment Company Limited holds 38,667,375 shares, representing a 31.36% stake.BF Investment Limited holds 3,273,375 shares, representing a 2.65% stake.Total promoter group holding declared as unencumbered amounts to 34.01% of the company.Disclosure is compliant with Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive indicator of promoter financial health and transparency. No immediate action is required as this is a routine but important annual compliance filing.
Hikal Q4 FY26: Revenue at ₹519 Cr, EBITDA Margin Hits 20.3%, Final Dividend of 20% Announced
Hikal reported a sequential recovery in Q4 FY26 with revenues of ₹519 crore and a strong EBITDA margin of 20.3%, up from 17% in the previous quarter. Net profit for the quarter stood at ₹14 crore, significantly impacted by a one-time exceptional impairment charge of ₹47 crore related to manufacturing assets at Panoli. The Crop Protection segment showed robust momentum with 45% QoQ growth, while the Pharma business recovered from H1 regulatory headwinds with H2 revenues growing 60% over H1. The board has recommended a final dividend of 20%, bringing the total dividend for FY26 to 30%.
முக்கிய அம்சங்கள்
Q4 Revenue reached ₹519 crore with EBITDA standing at ₹105 crore (20.3% margin).Exceptional item of ₹47 crore recorded for impairment of Panoli manufacturing asset.Crop Protection revenue grew 45% QoQ and 13% YoY to ₹228 crore.Pharma business H2 FY26 revenue grew by 60% to ₹629 crore compared to H1 FY26.Board approved a final dividend of 20% of Face Value, totaling 30% for the full year.
👀 கவனிக்க வேண்டியவை
Investors should focus on the operational turnaround and margin expansion which suggests the worst of the inventory cycle and regulatory hurdles is over. Monitor the commercialization of the new Personal Care and Specialty Chemicals segments in FY27 as potential growth drivers.
Hikal Q4 FY26: EBITDA Margins Recover to 20.3%; FY26 PAT Hit by ₹85 Cr Exceptional Items
Hikal reported a sequential recovery in Q4 FY26 with EBITDA margins rising to 20.3%, although revenue declined 6% YoY to ₹519 crore. The full-year FY26 performance was significantly impacted by exceptional charges totaling ₹85 crore related to new labor codes and asset impairments, resulting in a consolidated net loss of ₹49 crore compared to a ₹91 crore profit in FY25. Despite the annual loss, the company maintained its dividend policy, declaring a total dividend of 30% for the year. Management indicates that the worst of the cycle is over, with the Pharmaceutical segment showing a 60% revenue growth in H2 FY26 compared to H1 FY26.
முக்கிய அம்சங்கள்
Q4 FY26 EBITDA margin improved to 20.3% from 16.8% in Q3 FY26, signaling operational recovery.FY26 consolidated revenue fell 8% YoY to ₹1,713 crore, while EBITDA dropped 33% to ₹220 crore.Exceptional items of ₹85 crore (₹38 crore labor code and ₹47 crore impairment) led to an annual net loss of ₹49 crore.Pharmaceutical H2 FY26 revenue grew 60% over H1 FY26, recovering from earlier regulatory headwinds.Total dividend for FY26 stands at 30%, including a final dividend recommendation of 20%.
👀 கவனிக்க வேண்டியவை
Investors should focus on the sequential margin improvement and the strong H2 recovery in the Pharma segment as signs of a turnaround. However, the impact of exceptional items and competitive pricing in Crop Protection warrants a cautious 'Watch' approach until FY27 growth stabilizes.
Hikal Concludes Revenue Recognition Probe with No Financial Impact; Appoints New Segment President
Hikal Limited has provided a final update on employee irregularities first disclosed in December 2025 regarding revenue recognition timing. An external fact-finding review determined that the issues were restricted to the preponement of genuine sales and have no impact on current or past financial results. The company has terminated the responsible employees and strengthened internal controls to prevent recurrence. Simultaneously, Hikal has appointed Mr. Ravi Khadabadi as President of Crop Protection & Specialty Chemicals to lead the segment's growth.
முக்கிய அம்சங்கள்
External review confirmed irregularities were limited to preponement of genuine sales as of September 30, 2025.Management concludes there is no financial impact on the company's current or previous reporting periods.Responsible employees have been identified and relieved from their services at the company.Mr. Ravi Khadabadi appointed as President - Crop Protection & Specialty Chemicals effective May 27, 2026.
👀 கவனிக்க வேண்டியவை
The closure of the investigation without financial restatements reduces governance risk for the company. Investors should now focus on the execution of the Crop Protection business under the new leadership.
Hikal FY26 Revenue Drops 8% to ₹17,126M; Reports Net Loss of ₹487M
Hikal Limited faced a difficult financial year ending March 2026, reporting a standalone net loss of ₹487 million compared to a profit of ₹909 million in FY25. The performance was severely impacted by exceptional items amounting to ₹851 million and a 7.9% decline in annual revenue to ₹17,126 million. However, the company showed signs of recovery in Q4 FY26 with a net profit of ₹146 million, compared to a loss in the preceding quarter. The board recommended a final dividend of ₹0.40 per share, maintaining some payout despite the annual loss.
முக்கிய அம்சங்கள்
Annual revenue decreased by 7.9% YoY to ₹17,126 million in FY26 from ₹18,598 million.Full-year net loss stood at ₹487 million, significantly impacted by ₹851 million in exceptional charges.Q4 FY26 net profit was ₹146 million, a decline from ₹503 million in the same quarter last year.Final dividend of ₹0.40 per share (20%) recommended, bringing the total FY26 dividend to ₹0.60.Auditors flagged ongoing environmental litigation in the Supreme Court as an 'Emphasis of Matter'.
👀 கவனிக்க வேண்டியவை
The stock remains under pressure due to the significant annual loss and the legal overhang regarding environmental compliance. Investors should monitor the outcome of the Supreme Court proceedings and the company's ability to sustain the sequential recovery seen in Q4.
Hikal Reports FY26 Net Loss of ₹487 Million; Recommends ₹0.40 Final Dividend
Hikal Limited reported a weak set of results for FY 2025-26, swinging to a net loss of ₹487 million from a profit of ₹909 million in the previous year. Total revenue for the fiscal year declined by 7.9% to ₹17,126 million, primarily dragged down by exceptional items totaling ₹851 million. Despite the bottom-line pressure, the board has recommended a final dividend of ₹0.40 per share, bringing the total annual dividend to ₹0.60. The company also faces ongoing legal uncertainty regarding environmental compliance, which is currently pending before the Supreme Court.
முக்கிய அம்சங்கள்
Annual revenue from operations decreased to ₹17,126 million in FY26 from ₹18,598 million in FY25.Reported a consolidated net loss of ₹487 million for FY26 compared to a profit of ₹909 million in FY25.Exceptional items of ₹851 million significantly impacted the full-year profitability.Recommended a final dividend of ₹0.40 per share (20%), totaling ₹0.60 (30%) for the full year.Auditors issued an 'Emphasis of Matter' regarding ongoing environmental litigation in the Supreme Court.
👀 கவனிக்க வேண்டியவை
Investors should remain cautious as the company has moved into a loss-making position and faces significant legal/regulatory overhang. Monitor the Supreme Court's decision on environmental compliance and the company's strategy to offset exceptional costs in upcoming quarters.
Hikal Q3 FY26 Revenue at ₹494 Cr; EBITDA Margins Recover to 16.8% Amid Pharma Turnaround
Hikal reported a recovery in Q3 FY26 with consolidated revenue of ₹494 crores and a significantly improved EBITDA margin of 16.8%, driven by the Pharmaceutical segment's return to operational normalcy. The company declared an interim dividend of ₹0.2 per share despite a reported loss caused by a one-time exceptional charge of ₹38 crores related to new labor code provisions. While the Pharma division saw revenue of ₹337 crores, the Crop Protection business at ₹157 crores continues to face pricing headwinds from Chinese overcapacity. Management expects a stronger Q4 as remediation efforts regarding US FDA audits are nearly complete and new capacities become operational.
முக்கிய அம்சங்கள்
Q3 FY26 EBITDA stood at ₹83 crores with margins expanding to 16.8% compared to the 9M average of 9.6%Pharmaceutical segment revenue reached ₹337 crores with a 12.3% EBIT margin as supply resumed post-remediationA one-time exceptional charge of ₹38 crores for labor code compliance impacted the bottom line, though adjusted PBT grew 21%Debt-equity ratio remains stable at 0.58 with ₹100 crore capex spent during the first nine months of FY26Diversification into Personal Care is underway with 3-4 products expected to commercialize in FY27
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of the Pharma margin recovery and the successful ramp-up of the new specialty chemicals vertical in FY27. The stock is a 'Watch' for consistent execution following the completion of intensive regulatory remediation.
Hikal Declares ₹0.20 Interim Dividend; Sets Feb 17, 2026 as Record Date
Hikal Limited has declared an interim dividend of ₹0.20 per equity share (10% of face value) for the financial year 2025-26. The company has fixed February 17, 2026, as the record date to identify eligible shareholders, with the dividend payment scheduled to be completed by March 12, 2026. Investors are required to submit necessary tax documentation by February 18, 2026, to ensure appropriate Tax Deduction at Source (TDS) rates are applied. The standard TDS rate for resident shareholders with a valid PAN is 10%, provided the dividend exceeds ₹10,000.
முக்கிய அம்சங்கள்
Interim dividend of ₹0.20 per equity share (10% on face value of ₹2) for FY 2025-26.Record date for dividend eligibility is fixed as February 17, 2026.Dividend payment to be processed on or before March 12, 2026.TDS of 10% for residents with PAN; 20% for those without valid PAN or non-residents without treaty benefits.Deadline for submitting tax exemption forms (15G/15H/TRC) is February 18, 2026.
👀 கவனிக்க வேண்டியவை
Investors should ensure their PAN and bank account details are updated with their Depository Participant by February 17. To avoid higher tax withholding, eligible shareholders must submit Form 15G/15H or Tax Residency Certificates to the company by the February 18 deadline.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
